News & Updates

Precision medicine and tumour-agnostic approach are changing the landscape of non-small-cell lung cancer (NSCLC) and many other advanced solid tumours without satisfactory standard treatments. In an industry-sponsored meeting endorsed by the Hong Kong Society of Clinical Oncology, Professor Jürgen Wolf of the Center for Integrated Oncology, University of Cologne, Germany, lead investigator of an international phase II trial that led to the approval of capmatinib for advanced NSCLC harbouring MET exon 14 (METex14) skipping mutation, discussed the importance of panel molecular testing and targeted therapy in different solid tumours, focusing in particular on advanced NSCLC with actionable driver mutations, such as MET alterations.

In patients with low-risk cervical cancer, simple hysterectomy has demonstrated noninferior pelvic recurrence rate at 3 years and lower rates of surgery-related urologic adverse events (AEs) vs radical hysterectomy in the phase III, randomized, noninferiority CX.5 SHAPE trial.